Decision brings the innovative treatment to early-stage lung cancer patients, helping to address unmet need in this setting
News
Communications Awards winner shares insight into the competition
Lucinda Sandon-Allum of Langland and winner in the 2020 Aspiring Communications Manager of the Year shares her competition highlights.
Alchemab to collaborate with AstraZeneca on prostate cancer research
Collaboration will aim to improve understanding of prostate cancer and identify novel antibodies for the disease
Preliminary NICE ‘no’ for Merck’s Bavencio
The cost regulator has rejecting funding the drug as maintenance treatment of advanced/metastatic urothelial cancer
EC clears GSK’s Benlysta for lupus nephritis
The drug is the only biologic treatment approved in Europe that is specifically designed to work in systemic lupus erythematosus and lupus nephritis
US supports waiving IP for COVID vaccines
MSF has applauded the move, but the IFPMA said the decision is “disappointing”
Cumulus Neuroscience raises £6m in Dementia Discovery Fund-led financing round
Funds will be used to advance company’s integrated physiological and digital biomarker platform
Tecentriq approved for first-line metastatic NSCLC
Checkpoint inhibitor specifically approved for patients with high PD-L1 expression
NICE expands access for SMA drug Spinraza
Managed access agreement treatment eligibility criteria extended following review
UK bolsters COVID-19 variant testing capabilities with £29.3m investment
New facility will fast-track vaccines for COVID-19 variants to “future-proof the country”
CROY 2021 deadline extended to 18th June
The 2021 Clinical Researcher of the Year – The Americas competitions entry deadline has been extended to the 18th of June.
NHS rolls out 3D heart scans to fast-track diagnosis of heart disease
Scan enables doctors to diagnose coronary heart disease in 20 minutes, according to NHS England
Researchers identify new genetic target for acute myeloid leukaemia
Targeting a specific mutation in the CUX1 gene may offer a ‘new therapy avenue’ for AML patients
Janssen seeks EU approval for first CAR-T therapy cilta-cel
Cilta-cel is an investigational CAR-T cell therapy for the treatment of relapsed/refractory multiple myeloma
AZ’s Farxiga scores US approval in chronic kidney disease
SGLT2 inhibitor approved for high-risk patients with and without type 2 diabetes
